Integrated BioPharma, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a INBP research report →
Companywww.ibiopharma.com
Integrated BioPharma, Inc. , together with its subsidiaries, manufactures, distributes, markets, and sells vitamins, nutritional supplements, and herbal products primarily in the United States, Luxembourg, and Canada. It operates through Contract Manufacturing and Other Nutraceutical Businesses segments.
- CEO
- Riva Kay Sheppard
- IPO
- 1996
- Employees
- 147
- HQ
- Hillside, NJ, US
Price Chart
Valuation
- Market Cap
- $5.82M
- P/E
- -3.52
- P/S
- 0.12
- P/B
- 0.31
- EV/EBITDA
- 59.65
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 4.64%
- Op Margin
- -2.58%
- Net Margin
- -3.43%
- ROE
- -8.32%
- ROIC
- -5.58%
Growth & Income
- Revenue
- $54.35M · 8.02%
- Net Income
- $808.00K · 621.43%
- EPS
- $0.03 · 621.62%
- Op Income
- $2.02M
- FCF YoY
- 380.51%
Performance & Tape
- 52W High
- $0.42
- 52W Low
- $0.18
- 50D MA
- $0.27
- 200D MA
- $0.30
- Beta
- 0.30
- Avg Volume
- 6.53K
Get TickerSpark's AI analysis on INBP
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 15, 26 | Milmoe William H. | other | 8,966,547 |
| Apr 15, 26 | Milmoe William H. | other | 2,235,417 |
| Apr 15, 26 | DESANTIS CARL | other | 8,966,547 |
| Apr 15, 26 | DESANTIS CARL | other | 2,235,417 |
| Apr 15, 26 | DeSantis Damon | other | 2,235,417 |
| Apr 15, 26 | DeSantis Damon | other | 8,966,547 |
| Mar 24, 26 | DESANTIS CARL | other | 1,356,293 |
| Mar 24, 26 | DESANTIS CARL | other | 7,392 |
| Mar 24, 26 | Milmoe William H. | other | 1,356,293 |
| Mar 24, 26 | Milmoe William H. | other | 7,392 |
Our INBP Coverage
We haven't published any research on INBP yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate INBP Report →